DE69633180D1 - Verkapselte zellen die virenpartikeln produzieren - Google Patents

Verkapselte zellen die virenpartikeln produzieren

Info

Publication number
DE69633180D1
DE69633180D1 DE69633180T DE69633180T DE69633180D1 DE 69633180 D1 DE69633180 D1 DE 69633180D1 DE 69633180 T DE69633180 T DE 69633180T DE 69633180 T DE69633180 T DE 69633180T DE 69633180 D1 DE69633180 D1 DE 69633180D1
Authority
DE
Germany
Prior art keywords
encapsulated cells
virus particles
produce virus
cells
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633180T
Other languages
German (de)
English (en)
Inventor
Michael Saller
H Guenzburg
Brian Salmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschung De
Bavarian Nordic AS
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69633180(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, Bavarian Nordic AS filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Application granted granted Critical
Publication of DE69633180D1 publication Critical patent/DE69633180D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE69633180T 1995-06-27 1996-06-24 Verkapselte zellen die virenpartikeln produzieren Expired - Lifetime DE69633180D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK74095 1995-06-27
PCT/EP1996/002748 WO1997001357A1 (en) 1995-06-27 1996-06-24 Encapsulated cells producing viral particles

Publications (1)

Publication Number Publication Date
DE69633180D1 true DE69633180D1 (de) 2004-09-23

Family

ID=8097001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633180T Expired - Lifetime DE69633180D1 (de) 1995-06-27 1996-06-24 Verkapselte zellen die virenpartikeln produzieren

Country Status (21)

Country Link
US (1) US6776985B1 (enExample)
EP (1) EP0835137B1 (enExample)
JP (2) JP4119952B2 (enExample)
KR (1) KR100484883B1 (enExample)
CN (1) CN1187095C (enExample)
AT (1) ATE309000T1 (enExample)
AU (1) AU708273B2 (enExample)
CA (1) CA2222559A1 (enExample)
CZ (1) CZ286979B6 (enExample)
DE (1) DE69633180D1 (enExample)
DK (1) DK0835137T3 (enExample)
ES (1) ES2253754T3 (enExample)
IL (1) IL122119A (enExample)
NO (1) NO321427B1 (enExample)
NZ (1) NZ312671A (enExample)
PL (1) PL185338B1 (enExample)
PT (1) PT835137E (enExample)
RU (1) RU2187301C2 (enExample)
SI (1) SI0835137T1 (enExample)
UA (1) UA65525C2 (enExample)
WO (1) WO1997001357A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028563A1 (en) 1995-03-09 1996-09-19 Bavarian Nordic Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy
CZ286979B6 (en) 1995-06-27 2000-08-16 Bavarian Nordic Res Inst As Capsule encapsulating cells producing viral particles, process of its preparation and pharmaceutical preparation for gene therapy
IL125795A0 (en) 1996-03-27 1999-04-11 Bavarian Nordic Res Inst As Retroviral vectors encoding a cytochrome p450 gene
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
EP0994680A1 (en) 1998-05-05 2000-04-26 Koninklijke Philips Electronics N.V. Toothbrush comprising a brush member having a bristle field and an interdental bristle field
NZ550542A (en) 2004-03-30 2009-03-31 Nsgene As Therapeutic use of a growth factor, NsG33
US20090022785A1 (en) * 2005-05-03 2009-01-22 Veterinarmedizinische Universitat Wien Permeable Capsules
WO2009085850A2 (en) * 2007-12-20 2009-07-09 Ethicon, Incorporated Encapsulated kidney tissue
KR101250925B1 (ko) * 2011-10-28 2013-04-04 한화케미칼 주식회사 캡슐 세포용 구조체
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
KR102067352B1 (ko) * 2015-11-24 2020-01-16 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 레트로바이러스 생산을 위한 일시적인 형질감염 방법
US20170145388A1 (en) * 2015-11-24 2017-05-25 Glaxosmithkline Intellectual Property Development Limited Stable cell lines for retroviral production
AU2017269371B2 (en) 2016-05-25 2021-08-05 Lonza Houston Inc. Methods for isolating adeno-associated virus using a polydiallyldialkylammonium salt
RU2688383C2 (ru) * 2017-07-10 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Способ синтеза белка в культуре бактериальных клеток
JP2024519909A (ja) * 2021-05-21 2024-05-21 バイオナット ラブス リミテッド マイクロボット媒介治療送達のためのシステム及び方法
CN115820683B (zh) * 2022-09-28 2024-04-05 西南大学 家蚕Cyp9a20基因及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
DD160393A3 (de) * 1980-11-14 1983-07-27 Horst Dautzenberg Mikrokapseln und verfahren zu ihrer herstellung
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
AU631554B2 (en) 1988-05-17 1992-12-03 Sloan-Kettering Institute For Cancer Research Retroviral vector
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE4021050A1 (de) * 1990-06-29 1992-01-02 Akad Wissenschaften Ddr Verfahren zur herstellung von mikrokapseln
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
CA2098510A1 (en) * 1990-12-13 1992-06-14 Kenneth W. Culver Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
ATE200517T1 (de) 1994-09-02 2001-04-15 Gsf Forschungszentrum Umwelt Nicht selbstinaktivierende retrovirale vektoren mit gezielter expression
CZ286979B6 (en) 1995-06-27 2000-08-16 Bavarian Nordic Res Inst As Capsule encapsulating cells producing viral particles, process of its preparation and pharmaceutical preparation for gene therapy
ES2174103T3 (es) 1995-09-06 2002-11-01 Austrian Nordic Biotherapeutic Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
IL125795A0 (en) 1996-03-27 1999-04-11 Bavarian Nordic Res Inst As Retroviral vectors encoding a cytochrome p450 gene

Also Published As

Publication number Publication date
EP0835137B1 (en) 2005-11-09
HK1010139A1 (en) 1999-06-17
JP4848348B2 (ja) 2011-12-28
NO975813D0 (no) 1997-12-10
WO1997001357A1 (en) 1997-01-16
CZ286979B6 (en) 2000-08-16
JP4119952B2 (ja) 2008-07-16
KR100484883B1 (ko) 2005-09-02
DK0835137T3 (da) 2006-03-06
CA2222559A1 (en) 1997-01-16
EP0835137A1 (en) 1998-04-15
NZ312671A (en) 1999-10-28
CN1189104A (zh) 1998-07-29
RU2187301C2 (ru) 2002-08-20
UA65525C2 (en) 2004-04-15
ATE309000T1 (de) 2005-11-15
SI0835137T1 (sl) 2006-04-30
PT835137E (pt) 2004-12-31
JP2008101011A (ja) 2008-05-01
ES2253754T3 (es) 2006-06-01
US6776985B1 (en) 2004-08-17
NO321427B1 (no) 2006-05-08
NO975813L (no) 1998-02-23
CZ419597A3 (cs) 1998-03-18
PL324289A1 (en) 1998-05-11
KR19990028491A (ko) 1999-04-15
CN1187095C (zh) 2005-02-02
IL122119A (en) 2004-06-01
AU6415496A (en) 1997-01-30
AU708273B2 (en) 1999-07-29
PL185338B1 (pl) 2003-04-30
JPH11508768A (ja) 1999-08-03
IL122119A0 (en) 1998-04-05

Similar Documents

Publication Publication Date Title
DE69633180D1 (de) Verkapselte zellen die virenpartikeln produzieren
CA2092195A1 (en) Retroviral packaging cell line
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
UA40661C2 (uk) Вектор для введення бажаного гена у рослину (варіанти), спосіб одержання трансгенної рослини, спосіб введення, принаймні, двох бажаних генів у рослину
EP1103564A4 (en) CANCER ANTIGEN, BASED ON TUMOR SUPPRESSIVE GENEVA PRODUCT WT1
MX9700564A (es) Derivados de benzoilo y sintesis de los mismos.
EP0845032A4 (en) ISOLATED NUCLEIC ACID MOLECULES, PEPTIDES COMPLEX WITH HLA-A2 MOLECULES (MHC), AND THEIR USE
DK0742834T3 (da) Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot ce
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
GB9813540D0 (en) Chemical compounds
ATE298371T1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
DE59813758D1 (de) Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
MXPA05005545A (es) Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
RU2005129273A (ru) Противораковый агент, содержащий белок lk8 в качестве активного ингредиента
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
EP1070122A4 (en) INDUCTION OF APOPTIC OR CYTOTOXIC GENE EXPRESSION BY ADENOVIRUS-MEDIATED GENE TRANSFER
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
DE50200711D1 (de) Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
ES2068811T3 (es) Plantas resistentes a virus que tienen una proteina de cubierta viral.
MY104975A (en) Protease, reverse transcriptase and endonuclease of retrovirus, and method for producing these enzymes.
OA09197A (fr) "Peptides SDK, leur procédé de préparation ainsi que des compositions thérapeutiques en contenant".
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler

Legal Events

Date Code Title Description
8372 Publication of ep patent withdrawn
8327 Change in the person/name/address of the patent owner

Owner name: GSF-FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GM

Owner name: BAVARIAN NORDIC A/S, KVISTGAARD, DK

8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: BAVARIAN NORDIC A/S, KVISTGAARD, DK

Owner name: HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNG, DE